文献速递血脂与心血管预防

口服PCSK9抑制剂AZD0780治疗高胆固醇血症:PURSUIT随机试验

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-03-31

PURSUIT为2期随机双盲安慰剂对照多中心试验,评估口服PCSK9小分子抑制剂AZD0780在已接受中高强度他汀治疗的高胆固醇血症患者中的疗效与安全性。研究纳入428例患者,随机接受AZD0780 1、3、10、30 mg或安慰剂每日一次治疗12周。结果显示AZD0780呈剂量依赖性显著降低LDL-C,安慰剂校正的LS均值百分比变化达-35.3%至-50.7%,且安全耐受性良好。

要点

  • AZD0780每日一次口服12周,LDL-C降幅呈剂量依赖性,最高达-50.7%。
  • 基线他汀强度(中 vs 高)不影响AZD0780的降脂疗效。
  • 达到ACC/AHA高危患者LDL-C目标的比例随剂量增加而升高。

核心结论

  • AZD0780在已接受中高强度他汀治疗的高胆固醇血症患者中呈剂量依赖性显著降低LDL-C,安全耐受性良好,支持其作为每日一次口服药物进一步开发。

研究设计与样本

  • 2期随机、双盲、安慰剂对照、多中心PURSUIT试验,纳入空腹LDL-C≥70 mg/dL且<190 mg/dL、甘油三酯<400 mg/dL、稳定使用中或高强度他汀(可联用依折麦布)的患者。
  • 患者按1:1:1:1:1随机接受AZD0780 1、3、10、30 mg或匹配安慰剂口服每日一次,治疗12周。
  • 共随机428例患者,其中426例开始治疗;男性占52.1%,平均年龄62.4±7.6岁。

主要发现

  • 第12周时,AZD0780 1、3、10、30 mg组相比安慰剂的LDL-C最小二乘均值百分比变化差异分别为-35.3%(95%CI:-43.6%至-26.9%)、-37.9%(95%CI:-46.3%至-29.5%)、-45.2%(95%CI:-53.5%至-36.9%)和-50.7%(95%CI:-59.0%至-42.4%)。
  • 基线他汀使用强度(中等 vs 高强度)未改变AZD0780的疗效。
  • 达到ACC/AHA指南高危患者LDL-C目标的比例呈剂量比例性增加。
  • AZD0780总治疗组不良事件发生率为38.2%,安慰剂组为32.6%。

关键数值与推荐

  • 主要疗效终点为第12周LDL-C较基线的百分比变化。
  • 入组标准:空腹LDL-C≥70 mg/dL(1.8 mmol/L)且<190 mg/dL(4.9 mmol/L),甘油三酯<400 mg/dL。
  • 安全性评估包括不良事件数量、生命体征、心电图和实验室检查。

临床怎么用

  • 对于已接受中高强度他汀治疗但LDL-C未达标的高危患者,口服PCSK9抑制剂AZD0780可能提供一种每日一次的非注射降脂选择。
  • 疗效呈剂量依赖性,支持后续3期试验进一步确定最佳剂量。

局限性

  • 为2期试验,样本量428例,治疗时长仅12周。
  • 未报告长期心血管结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients at high-risk for cardiovascular events do not achieve lipid goals advocated by American College of Cardiology/American Heart Association (ACC/AHA) guidelines despite the wide availability of lipid-lowering therapy. AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia. OBJECTIVES: The phase 2 randomized, double-blind, placebo-controlled, multicenter PURSUIT trial evaluated the efficacy and safety of AZD0780 in patients with hypercholesterolemia already on background moderate-to-high-intensity statin treatment. METHODS: Eligible study patients had a fasting low-density lipoprotein cholesterol (LDL-C) level of ≥70 mg/dL (1.8 mmol/L) and <190 mg/dL (4.9 mmol/L), and triglycerides <400 mg/dL on stable dose of moderate- or high-intensity statins, as defined by ACC/AHA or local guidelines, with or without ezetimibe at baseline. The study randomized patients 1:1:1:1:1 to receive AZD0780 1, 3, 10, or 30 mg, or matching placebo, oral once daily, for 12 weeks. The primary efficacy endpoint was percent change of LDL-C from baseline to week 12. Safety and tolerability evaluations included the number of adverse events, vital signs, electrocardiograms, and laboratory assessments. RESULTS: In total, the study randomized 428 patients, of whom 426 started treatment. Patients were 52.1% male, with an average age of 62.4 ± 7.6 years. At week 12, compared with baseline, the placebo-corrected difference in least squares mean percent change of LDL-C for AZD0780 1, 3, 10, and 30 mg vs placebo was -35.3% (95% CI: -43.6% to -26.9%), -37.9% (95% CI:-46.3% to -29.5%), -45.2% (95% CI: -53.5% to -36.9%), and -50.7% (95% CI: -59.0% to -42.4%), respectively. Baseline statin use, moderate vs high intensity, did not alter AZD0780 efficacy. The proportion of patients reaching the ACC/AHA guideline LDL-C goal for high-risk patients increased in a dose-proportional manner. Adverse events compared similarly between the total AZD0780 treatment group (38.2%) and placebo (32.6%). CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment. (A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia [PURSUIT]; NCT06173570).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Koren MJ, Vega RB, Agrawal N, et al. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025. PMID: 40167413. doi:10.1016/j.jacc.2025.03.499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。